MaxCyte, Inc. is a medium risk pharmaceutical company in the United States that specializes in commercial cell engineering. They provide platform technologies to support the discovery, development, and commercialization of next-generation cell therapeutics and aid cell-based research and development. MaxCyte has a proprietary Flow Electroporation platform that enables complex cell engineering. Revenue is generated through the sale and licensing of their instruments and disposable processing assemblies. Their ESG score is 27.5.